Asymmetric dimethylarginine (ADMA)-A modulator of nociception in opiate tolerance and addiction?

Nitric Oxide - Biology and Chemistry

Volumn 17, Issue 2, 2007, Pages 55-59

  Kielstein, Anousheh ^a   Tsikas, Dimitrios ^b   Galloway, Gantt P ^a   Mendelson, John E ^a  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Addiction; Asymmetric dimethylarginine; Heroine; NG monomethyl l arginine; Nociception; NOS; Opiates

Indexed keywords

DIMETHYLARGININASE; MU OPIATE RECEPTOR; MYELIN; N(G) METHYLARGININE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

ARTICLE; ELECTROENCEPHALOGRAM; ENZYME METABOLISM; MORPHINE TOLERANCE; NOCICEPTION; NONHUMAN; OPIATE ADDICTION; PAIN THRESHOLD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION;

ANALGESICS, OPIOID; ARGININE; DRUG TOLERANCE; HUMANS; NITRIC OXIDE SYNTHASE TYPE I; OPIOID-RELATED DISORDERS; PAIN;

MUS; RATTUS;

EID: 34547901364     PISSN: 10898603     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.niox.2007.05.005     Document Type: Article

References (37)

1. Kakimoto Y., and Akazawa S. Isolation and identification of N-G, N-G- and N-G, N′-G-dimethyl-arginine, N-epsillon-mono-, di-, and trimethyllysine, and glucosylgalactosyl- and galactosyl-delta-hydroxylysine from human urine. J. Biol. Chem. 245 (1970) 5751-5758
2. Nakajima T., Matsuoka Y., and Kakimoto Y. Isolation and identification of N-G-monomethyl, N-G, N-G-dimethyl- and N-G, N′G-dimethylarginine from the hydrolysate of proteins of bovine brain. Biochim. Biophys. Acta 230 (1971) 212-222
3. Najbauer J., Johnson B., Young A., and Aswad D. Peptides with sequences similar to glycine, arginine-rich motifs in proteins interacting with RNA are efficiently recognized by methyltransferase(s) modifying arginine in numerous proteins. J. Biol. Chem. 268 (1993) 10501-10509
4. Ghosh S., Paik W., and Kim S. Purification and molecular identification of two protein methylases I from calf brain myelin basic protein-and histone-specific enzyme. J. Biol. Chem. 263 (1988) 19024-19033
5. Rajpurohit R., Paik W., and Kim S. Enzymatic methylation of heterogenous nuclear ribonucleoprotein in isolated liver nuclei. Biochim. Biophys. Acta 1122 (1992) 183-188
6. Leiper J., and Vallance P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc. Res. 43 (1999) 542-548
7. Cardounel A.J., and Zweier J.L. Endogenous methylarginines regulate neuronal nitric-oxide synthase and prevent excitotoxic injury. J. Biol.Chem. 277 (2002) 33995-34002
8. Cardounel A.J., Xia Y., and Zweier J.L. Endogenous methylarginines modulate superoxide as well as nitric oxide generation from neuronal nitric-oxide synthase: differences in the effects of monomethyl- and dimethylarginines in the presence and absence of tetradihydrobiopterin. J. Biol. Chem. 280 (2005) 7540-7549
9. Vallance P., Leone A., Calver A., Collier J., and Moncada S. Accumulation of and endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339 (1992) 572-575
10. McDermott J. Studies on the catabolism of Ng-methylarginine, N-G, N-G-dimethylarginine and N-G, N-G-dimethylarginine in the rabbit. Biochem. J. 154 (1976) 179-184
11. Ogawa T., Kimoto M., and Sasaoka K. Purification and properties of a new enzyme, N-G, N-G-dimethylarginine dimethylaminohydrolase, from rat kidney. J. Biol. Chem. 264 (1989) 10205-10209
12. McCarty M.F. Vascular endothelium is the organ chiefly responsible for the catabolism of plasma asymmetric dimethylarginine-an explanation for the elevation of plasma ADMA in disorders characterized by endothelial dysfunction. Med. Hypotheses 63 (2004) 699-708
13. Tran C.T., Fox M.F., Vallance P., and Leiper J.M. Chromosomal localization, gene structure, and expression pattern of DDAH1: comparison with DDAH2 and implications for evolutionary origins. Genomics 68 (2000) 101-105
14. Schuman E.M., and Madison D.V. Nitric oxide and synaptic function. Annu. Rev. Neurosci. 17 (1994) 153-183
15. Tsikas D., Boger R.H., Sandmann J., Bode-Boger S.M., and Frolich J.C. Endogenous nitric oxide synthase inhibitors are responsible for the l-arginine paradox. FEBS Lett. 478 (2000) 1-3
16. Teerlink T., Nijveldt R., deJong S., and VanLeeuwen P. Determination of Arginine, Asymmetric Dimethylarginine, and Symmetric Dimethylarginine in Human Plasma and Other Biological Samples by High-Performance Liquid Chromatography. Anal. Biochem. 303 (2002) 137
17. Anderstam B., Katzarski K., and Bergstrom J. Serum levels of NG, NG-dimethyl-l-arginine, a potential endogenous nitric oxide inhibitor in dialysis patients. J. Am. Soc. Nephrol. 8 (1997) 1437-1442
18. Itzhak Y. Modulation of cocaine- and methamphetamine-induced behavioral sensitization by inhibition of brain nitric oxide synthase. J. Pharmacol. Exp. Ther. 282 (1997) 521-527
19. Itzhak Y., Ali S., Martin J., Black M., and Huang P. Resistance of neuronal nitric oxide synthase-deficient mice to cocaine-induced locomotor sensitization. Psychopharmacology 140 (1998) 378-386
20. Zarrindast M., Gholami A., Sahraei H., and Haeri-Rohani A. Role of nitric oxide in the acquisition and expression of apomorphine- or morphine-induced locomotor sensitization. Eur. J. Pharmacol. 482 (2003) 205-213
21. Itzhak Y. Attenuation of cocaine kindling by 7-nitroindazole, an inhibitor of brain nitric oxide synthase. Neuropharmacology 35 (1996) 1065-1073
22. Itzhak Y., Martin J., Black M., and Huang P. The role of neuronal nitric oxide synthase in cocaine-induced conditioned place preference. Neuroreport 9 (1998) 2485-2488
23. Karami M., Zarrindast M., Sepehri H., and Sahraei H. Role of nitric oxide in the rat hippocampal CA1 area on morphine-induced conditioned place preference. Eur. J. Pharmacol. 449 (2002) 113-119
24. Heinzen E., and Pollack G. Pharmacodynamics of morphine-induced neuronal nitric oxide production and antinociceptive tolerance development. Brain Res. 1023 (2004) 175-184
25. Heinzen E., Brooth R., and Pollack G. Neuronal nitric oxide modulates morphine antinociceptive tolerance by enhancing constitutive activity of the μ-opioid receptor. Biochem. Pharmacol. 69 (2005) 479-488
26. Liu J., and Prather P. Chronic exposure to μ-opioid agonists produces constitutive activation of mu-opioid receptors in direct proportion to the efficacy of the agonist used for pretreatment. Mol. Pharmacol. 60 (2001) 53-62
27. Zhu W., Ma Y., and Bell A. Presence of morphine in rat amygdala: evidence for the 3 opiate receptor subtype via nitric oxide release in limbic structures. Med. Sci. Monit. 10 (2004) BR433-BR439
28. Pol O., Sasaki M., Jimenez N., Dawson V.L., Dawson T.M., and Puig M.M. The involvement of nitric oxide in the enhanced expression of μ-opioid receptors during intestinal inflammation in mice. Br. J. Pharmacol. 145 (2005) 758-766
29. Cuellar B., Fernandez A.P., Lizasoain I., Moro M.A., Lorenzo P., Bentura M.L., Rodrigo J., and Leza J.C. Up-regulation of neuronal NO synthase immunoreactivity in opiate dependence and withdrawal. Psychopharmacology (Berl) 148 (2000) 66-73
30. Yoo J.H., Cho J.H., Lee S.Y., Lee S., Loh H.H., Ho I.K., and Jang C.G. Differential effects of morphine- and cocaine-induced nNOS immunoreactivity in the dentate gyrus of hippocampus of mice lacking μ-opioid receptors. Neurosci. Lett. 395 (2006) 98-102
31. Vaupel D.B., Kimes A.S., and London E.D. Comparison of 7-nitroindazole with other nitric oxide synthase inhibitors as attenuators of opioid withdrawal. Psychopharmacology (Berlin) 118 (1995) 361-368
32. Vaupel D.B., Kimes A.S., and London E.D. Nitric oxide synthase inhibitors. Preclinical studies of potential use for treatment of opioid withdrawal. Neuropsychopharmacology 13 (1995) 315-322
33. Rosenkranz H.S., and Mermelstein R. Mutagenicity and genotoxicity of nitroarenes. All nitro-containing chemicals were not created equal. Mutat. Res. 114 (1983) 217-267
34. Santamarta M.T., Ulibarri I., and Pineda J. Inhibition of neuronal nitric oxide synthase attenuates the development of morphine tolerance in rats. Synapse 57 (2005) 38-46
35. Javelle N., Bérod A., Renaud B., and Lambás-Señas L. NO synthase inhibitors attenuate locus coeruleus catecholamine metabolism and behavior induced by morphine withdrawal. Neuroreport 13 (2002) 725-728
36. Leiper J., Nandi M., Torrondel B., Murray-Rust J., Malaki M., O'Hara B., Rossiter S., Anthony S., Madhani M., Selwood D., Smith C., Wojciak-Stothard B., Rudiger A., Stidwill A., McDonald N.Q., and Vallance P. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat. Med. 13 (2007) 198-2003
37. Kielstein J.T., and Zoccali C. Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age?. Am. J. Kidney Dis. 46 (2005) 186-202